AxoGen, Inc. Selected to Present at SEMDA 2014 Conference
AxoGen selected as one of 20 presenting companies
ALACHUA, FL - May 5, 2014 - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion U.S. peripheral nerve repair market, announced today that it has been selected from a record number of applicants as a presenting company at the 2014 Conference of the Southeastern Medical Device Association (SEMDA). The eighth annual SEMDA Conference, "Thriving During Healthcare Reform," will be held May 7-8, 2014, at the Renaissance Atlanta Waverly Hotel and Convention Center in Atlanta.
AxoGen Senior Vice President Jill Schiaparelli will give the presentation on behalf of the Company at 3:05 pm EST on Wednesday, May 7. Simultaneously, a copy of the presentation will be made available on the Investor section of the Company's website, http://ir.axogeninc.com/.
The Southeastern Medical Device Association (SEMDA) is a non-profit trade association that supports and promotes Medical Device and Medical Device Data Systems (MDDS) companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. Learn more at www.semda.net.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our projected 2014 revenue and gross margin, product development, product potential, financial performance, liquidity, sales growth, product adoption, market awareness of our products. and our visibility at and sponsorship of conferences and educational events The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: AxoGen, Inc.
Greg Freitag, Chief Financial Officer & General Counsel
Released May 5, 2014